Wednesday, February 06, 2019 CO17 citation: A PHASE III RANDOMIZED STUDY OF CETUXIMAB (ERBITUXTM, C225) AND BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE IN PATIENTS WITH PRETREATED METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)-POSITIVE COLORECTAL CARCINOMA (NCT00079066) Sud S, O'Callaghan C, Jonker C, Karapetis C, Price T, Tebbutt N, Shapiro J, van Hazel G, Pavlakis N, Gibbs P, Jeffrey M, Siu L, Gill S, Wong R, Jonker D, Tu D, Goodwin R. Hypertension as a predictor of advanced colorectal cancer outcome and cetuximab treatment response. Curr Oncol 2018/12/01: e516-e526, 2018. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291274/ This randomized phase III was studying cetuximab and best supportive care to see how well they work compared to best supportive care alone in treating patients with metastatic epidermal growth factor receptor-positive colorectal cancer. LY11 citation: A Randomized Phase III Trial Comparing Early High Dose Chemoradiotherapy and an Autologous Stem Cell Transplant to Conventional Dose CHOP Chemotherapy Plus Rituximab for CD20+B-Cell Lymphomas (With Possible Late Autologous Stem Cell Transplant)for Patients With Diffuse Aggressive Non-Hodgkin's Lymphoma in the High-Intermediate/High Risk International Classification Prognostic Groups. Al-Mansour Z, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Smith SM, Marcellus DC, Barton KP, Mills GM, LeBlanc M, Rimsza LM, Forman SJ, Leonard JP, Fisher RI, Friedberg JW, Stiff PJ. Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis (ONLINE). Leuk Lymphoma 1-8, 2019. https://www.tandfonline.com/doi/full/10.1080/10428194.2018.1563691?scroll=top&needAccess=true
